On October 2, 2023, Greg Weaver provided notice of his resignation as the Executive Vice President and Chief Financial Officer of Atossa Therapeutics, Inc. (the ?Company?), with such resignation to be effective following a 30-day notice period. Mr. Weaver tendered his resignation to pursue other opportunities and not due to any disagreement with the Company. The Company has elected to waive the notice period, which accelerated Mr. Weaver?s resignation effective date to October 5, 2023 (the ?Effective Date?).

Pursuant to his employment agreement with the Company, dated as of June 1, 2023, Mr. Weaver?s termination of service as an employee served as his resignation from all other positions with the Company, including as a member of the Board of Directors. Mr. Weaver had been serving as the Company?s principal financial and accounting officer. In connection with Mr. Weaver?s resignation, the Company has appointed Heather Rees, age 51, as the Company?s principal financial and accounting officer.

Ms. Rees has served as the Company?s Vice President, Finance and Accounting since 2021. Prior to that time, Ms. Rees served as the Company?s controller since 2017. Ms. Rees previously spent ten years working as an independent financial consultant serving public and private companies including Avalara, Getty Images, Fisher Communications, and Flow International.

She began her career with Deloitte & Touche and worked nine years in the audit practice. Ms. Rees earned a Bachelor of Business Administration in accounting from Gonzaga University.